North Point RX, LLC v. Key Therapeutics, LLC

CourtDistrict Court, S.D. Mississippi
DecidedMay 19, 2025
Docket3:25-cv-00020
StatusUnknown

This text of North Point RX, LLC v. Key Therapeutics, LLC (North Point RX, LLC v. Key Therapeutics, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. Mississippi primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
North Point RX, LLC v. Key Therapeutics, LLC, (S.D. Miss. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF MISSISSIPPI NORTHERN DIVISION NORTH POINT RX, LLC PETITIONER V. CIVIL ACTION NO. 3:25-CV-20-KHJ-MTP KEY THERAPEUTICS, LLC RESPONDENT a/k/a KEY THERAPUTICS, INC.

ORDER Before the Court is Petitioner North Point RX, LLC’s (“North Point”) [1] Petition to Confirm Arbitration Award, Respondent Key Therapeutics, LLC’s (“Key”) [9] Second Motion for Extension of Time to File Answer, Key’s [13] Motion to Vacate Arbitration Award, and Key’s [21] Motion to Strike. The Court denies the [9, 13, 21] Motions; the Court grants the [1] Petition and confirms the arbitral award.

I. Background North Point moves to confirm the arbitral award issued in the [1-1] Modified Final Order. [1-1] at 8–9; [1] ¶¶ 15–26. A timeline sharpens the picture. In 2022, North Point and Key entered into an [17-4] Agreement to commercialize pharmaceutical products. Tedrow Decl. [1-2] ¶ 4. Following some discourse between the parties, Key determined to terminate their [17-4] Agreement in 2023, and North Point filed an arbitration claim. [1-2] ¶¶ 7-8; | see also [17-4] at 32. The original [1-3] Final Order was entered on October 2, 2023. [1] 4 13. But later, North Point requested the Arbitrator modify the [1-3] Final Order because of Key’s additional harmful that caused further damages and exacerbated ongoing harm resulting from Key’s noncompliance. [1] § 13. North Point provided evidence ... that Key improperly blocked North Point’s access to a bank account the parties established (Bank Account’) pursuant to the [17-4] Agreementl,] along with evidence that Key had drained the Bank Account of almost all of the revenue generated from the sale of the pharmaceutical products owned by North Point. [1] 14 (citing [1-2] 94 10-16). So on October 18, 2023, the Arbitrator issued the [1-1] Modified Final Order, citing “Key’s failure to comply with the initial [1-3] Final Order.” [1] □□ 16-17. On September 16, 2024, North Point timely filed a [1] Petition to Confirm Arbitration Award, seeking the confirmation of the [1-1] Modified Final Order of the International Court of Arbitration. [1] § 17; [1-1] at 1, 10. This [1-1] Order “awarded relief in favor of North Point and against [Key].” [1] at 1. Specifically, under the [1- 1] Order (a) Key is ordered to deposit in the [Bank Account] . . . opened and maintained in accordance with Section 3 of Schedule A to the Agreement ... the sum of $500,000 . . . within five business days following the date of notification of this [1-1] Modified Final Order|;] (b) Key is ordered to comply with the requirement in Section 3 that all “sross sales” as defined in the Agreement are deposited in the Bank Account[;]

1 “North Point commenced the Arbitration to compel contractually required actions by Key as part of the commercial wind down process established by the [17-4] Agreement.” [1] { 11 (citing [1-2] 44 4-15).

(c) Key is enjoined from making any disbursements from, or otherwise encumbering, the Bank Account, except (i) to pay “Commercialization Expenses” as defined in Section 3, or (ii) as otherwise approved in writing by North Point, which approval shall not be unreasonably withheld[;] (d) Key is enjoined from prohibiting North Point’s access to view transactions occurring with the Bank Account and is ordered to restore North Point’s visibility to the Bank Account[;]

(e) Key is ordered, within three business days after notification of this [1-1] Modified Final order, to execute and submit to the FDA . . . all required documents and information to transfer the NDA . . . and otherwise cooperate with North Point by complying with all requests by North Point in the transfer process set forth in Section 10.3.3 of the [17-4] Commercialization Agreement[.]

[1-1] at 8–9 (cleaned up). According to North Point, however, “Key has not complied with any of the required items ordered by the Arbitrator except for subsection (e), and even then Key was in violation of the [1-1] Modified Final Order because its compliance was extremely untimely.” [1] ¶ 22. “[T]he total amount . . . that Key must deposit back into the Bank Account, in order to comply with the [1-1] Modified Final Order is $2,339,602.88.” [1] ¶ 18. So North Point petitioned this Court to confirm the [1-1] Modified Order. [1]. On November 18, 2024, Key filed an unopposed [5] Motion to Extend Deadline to File a Response, which was granted, allowing a 25-day extension. 11/19/2024 Text Only Order. Then two days before the new deadline, Key filed a [9] Second Motion for Extension of Time to File Answer and a First Motion to Stay Proceedings. North Point responded in opposition, arguing Key’s attempt “to delay the confirmation and enforcement of a valid final arbitration award” was “unjustified, in contravention of the Federal Arbitration Act (FAA’), prejudicial to North Point, and rlaln counter to judicial economy and efficiency.” Mem. Supp. Resp. [12] at 1; see also Resp. [11]. On January 3, 2025, Key filed both its [14] Reply to the [11] Response and a [13] Motion to Vacate Arbitration Award. In its [14] Reply, Key explains that it objects to the [1] Petition, see a/so Rebuttal [19],? and that “the affirmative misconduct and the material omissions of Tyler Tedrow (“Tedrow”), North Point’s apparent new President, demonstratel] why an extension was requested.” [14] at 1. And in its [13] Motion and [16] Memorandum in Support, Key argues the Court should vacate the arbitration award because it “was procured by ‘corruption, fraud, or undue means’ on the part of North Point.” [16] at 1-2 (referencing 9 U.S.C. § 10(a)(1)). In its [17] Response, North Point claims Key’s [13] Motion is time-barred and fails “to establish any fraudulent statement made to the Arbitrator or relevant to the arbitration process; faills] to show how the allegedly fraudulent statements made prior to and outside the arbitration process are material; and faills] to show they exercised due diligence before or during the arbitration proceeding.” [17] at 1. Key then replies that North Point “neglected to address” whether Tedrow “had authority to seek arbitration in the first place,” and that equitable tolling applies to the three-month statute of limitations set forth by the FAA. Reply [23] at 1, 4-6.

2 The filing of the [19] Rebuttal moots the [9] Second Motion for Extension of Time to File Answer to North Point’s [1] Petition.

In the same breath, Key also filed a [21] Motion to Strike “an unsworn expert report from Krista Tongring,” id. at 1, which was attached to North Point’s [17] Response. See Tongring Statement [17-13]. According to Key, the [17-13] Report is “1) unsworn, 2) fail to comply with [Federal Rule of Civil Procedure] 26I,] and 3) constitutes hearsayl,so] it must be stricken.” [21] at 1. In its [24] Response, North Point argues Tongring’s [17-13] Statement is “incorrectly referred to as an ‘expert report.” [24] at 1. Specifically, “[t]he [17-13] [Sltatement was provided to correct incorrect and irrelevant personal attacks, and it was given in the context of the confirmation process, which disfavors discovery.” [24] at 1. Still, North Point submitted an [24-1] Amended Statement of Tongring. See id. Finally, Key argues that the [24] Response and accompanying [25] Memorandum serve as “a de facto sur-reply,” and so they are “not allowed by the Local Rules of Civil Procedure without leave of the Court.” Reply [26] at 1 (citing L.U. Civ. R. 7(b)). Key explains the Court should strike the [24] Response because it “is outside of the scope of Key’s [21] Motion to Strikel,] as well as Tongring’s new expert opinion.” [26] at 3. The Court addresses the remaining pending motions below. Il. Analysis A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brown v. Witco Corporation
340 F.3d 209 (Fifth Circuit, 2003)
Hall Street Associates, L. L. C. v. Mattel, Inc.
552 U.S. 576 (Supreme Court, 2008)
Cigna Insurance v. Huddleston
986 F.2d 1418 (Fifth Circuit, 1993)
Morgan Keegan & Company, Inc. v. John Garrett, et
495 F. App'x 443 (Fifth Circuit, 2012)
Smith v. Shell Chemical Co.
333 F. Supp. 2d 579 (M.D. Louisiana, 2004)
BNSF Railway Company v. Alstom Transportation, Inc
777 F.3d 785 (Fifth Circuit, 2015)
Chester McVay v. Halliburton Energy Svcs, Inc.
608 F. App'x 222 (Fifth Circuit, 2015)
Move, Inc. v. Citigroup Global Markets, Inc.
840 F.3d 1152 (Ninth Circuit, 2016)
OOGC America, L.L.C. v. Chesapeake Exploration, L.
975 F.3d 449 (Fifth Circuit, 2020)
Badgerow v. Walters
596 U.S. 1 (Supreme Court, 2022)
Cooper v. Westend Capital Management, L.L.C.
832 F.3d 534 (Fifth Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
North Point RX, LLC v. Key Therapeutics, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/north-point-rx-llc-v-key-therapeutics-llc-mssd-2025.